Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Innate Pharma S.A. | Lacutamab (IPH4102) - (TELLOMAK 3) | Mycosis Fungoides, Sézary Syndrome | Phase 3 | Trial Planned | Intravenous | Oncology |
| Innate Pharma S.A. | Avdoralimab - (FORCE) | COVID-19 | Phase 2 | Trial Discontinued | Intravenous | COVID-19 |
| Innate Pharma S.A. | Durvalumab in combination with monalizumab or oleclumab - (PACIFIC-9) | Stage III non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | Intravenous | Oncology |
| Innate Pharma S.A. | Monalizuma - (NeoCOAST-2) | Early-stage non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Intravenous | Oncology |
| Innate Pharma S.A. | Monalizumab in combination with cetuximab + durvalumab | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 2 | Trial Completed | Intravenous | Oncology |
| Innoviva Inc. | LJPC-401 | Beta thalassemia patients suffering from iron overload | Phase 2 | Trial Discontinued | Subcutaneous | Hematology |
| Innoviva Inc. | LJPC‚Äë401 | Hereditary Hemochromatosis | Phase 2 | Trial Discontinued | Subcutaneous | Genetic Disorder |
| Inovio Pharmaceuticals Inc. | INO-4201 | Ebola | Phase 2 | Trial Planned | Intramuscular | Antiviral |
